8 completed, 1 recruiting, 1 terminated, 1 withdrawn. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow tetrathiomolybdate: new trials by email Literature Review of tetrathiomolybdate trials Research Report on tetrathiomolybdate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tetrathiomolybdate (TM) Plus Capecitabine Tetrathiomolybdate, Capecitabine, Pembrolizumab - Triple Negative Breast Cancer, Residual Disease | Phase 1 / Phase 2 | Recruiting | Dartmouth-Hitchcock Medical Center | 204 | 2024-11-26 | 2026-04-20 |
| Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants ALXN1840, Bupropion Hydrochloride - Wilson Disease | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 54 | 2020-10-21 | 2023-08-31 |
| A Study of the Cardiac Effects of ALXN1840 in Healthy Adults ALXN1840, Placebo, Moxifloxacin - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 57 | 2020-07-24 | 2023-08-14 |
| Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. ALXN1840, Celecoxib - Wilson Disease | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 36 | 2020-07-07 | 2023-08-21 |
| Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults ALXN1840 - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 48 | 2019-07-04 | 2023-08-02 |
| A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2014-04-07 | 2023-08-02 |
| A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults ALXN1840, Omeprazole - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2014-01-20 | 2023-08-01 |
| Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer Tetrathiomolybdate - Non-Small Cell Lung Cancer | Phase 1 | Completed | University of Rochester | 26 | 2013-11-01 | 2019-07-19 |
| Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis - Lung Cancer | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2007-05-01 | 2022-10-03 | |
| A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma ATN-224 + bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Attenuon | 46 | 2006-06-01 | 2008-10-28 |
| Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis Tetrathiomolybdate - Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | Completed | University of Michigan | 23 | 2003-03-01 | 2013-02-06 |
Hepatolenticular Degeneration (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Idiopathic Pulmonary Fibrosis (1) · Multiple Myeloma (1) · Neoplasm, Residual (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
Alexion Pharmaceuticals, Inc. (6) · Attenuon (1) · Dartmouth-Hitchcock Medical Center (1) · Roswell Park Cancer Institute (1) · University of Michigan (1) · University of Rochester (1)
United States (10) · United Kingdom (1)
David Dougherty, MD (1) · Eugene S. Swenson, MD, PhD (1) · Gilad Gordon, MD (1) · Kevin R Flaherty, MD, MS (1) · Linda Vahdat, MD (1) · Masood Sadaat, MD, MSc (1) · Mohammad K. Khan, MD, PhD (1)
2019 (1), R01CA290013 (1)